Effect of Size and Heterogeneity of Samples on Biomarker Discovery: Synthetic and Real Data Assessment

Barbara Di Camillo¹, Tiziana Sanavia¹, Matteo Martini¹, Giuseppe Jurman², Francesco Sambo¹, Annalisa Barla³, Margherita Squillario³, Cesare Furlanello², Gianna Toffolo¹, Claudio Cobelli¹*

¹ Information Engineering Department, University of Padova, Padova, Italy, ² Fondazione Bruno Kessler, Povo, Trento, Italy, ³ Department of Computer and Information Science, University of Genova, Genova, Italy

Abstract

Motivation: The identification of robust lists of molecular biomarkers related to a disease is a fundamental step for early diagnosis and treatment. However, methodologies for the discovery of biomarkers using microarray data often provide results with limited overlap. These differences are imputable to 1) dataset size (few subjects with respect to the number of features); 2) heterogeneity of the disease; 3) heterogeneity of experimental protocols and computational pipelines employed in the analysis. In this paper, we focus on the first two issues and assess, both on simulated (through an in silico regulation network model) and real clinical datasets, the consistency of candidate biomarkers provided by a number of different methods.

Methods: We extensively simulated the effect of heterogeneity characteristic of complex diseases on different sets of microarray data. Heterogeneity was reproduced by simulating both intrinsic variability of the population and the alteration of regulatory mechanisms. Population variability was simulated by modeling evolution of a pool of subjects; then, a subset of them underwent alterations in regulatory mechanisms so as to mimic the disease state.

Results: The simulated data allowed us to outline advantages and drawbacks of different methods across multiple studies and varying number of samples and to evaluate precision of feature selection on a benchmark with known biomarkers. Although comparable classification accuracy was reached by different methods, the use of external cross-validation loops is helpful in finding features with a higher degree of precision and stability. Application to real data confirmed these results.

Citation: Di Camillo B, Sanavia T, Martini M, Jurman G, Sambo F, et al. (2012) Effect of Size and Heterogeneity of Samples on Biomarker Discovery: Synthetic and Real Data Assessment. PLoS ONE 7(3): e32200. doi:10.1371/journal.pone.0032200

Editor: Jo-Ann L. Stanton, University of Otago, New Zealand

Received June 30, 2011; Accepted January 24, 2012; Published March 5, 2012

Copyright: © 2012 Di Camillo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the European Union’s Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under grant agreement n. 604517 (the SUMMIT consortium); ATENEO 2009/2010 “Methods for the integration of background knowledge in kernel-based learning algorithms for the robust identification of biomarkers in genomics” CPDA084142; CARIPARO 2008/2010 “Systems biology approaches to infer gene regulation from gene and protein time series data”; RF Project 2007 Conv. 42. ISITAD; EU-FP7 HiperDART. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: cobelli@dei.unipd.it

Introduction

In the last decade, transcriptome analysis performed with high-throughput microarrays has experienced a huge diffusion and has profoundly changed the approach to the study of complex diseases. In an experimental design, the data typically come from different subjects and phenotypes. The analysis of these data has proven extremely useful for the identification of biomarker genes and for the development of new physiologic hypotheses useful for answering diagnostic, prognostic and functional questions. However, for complex diseases such as cancer, the high-throughput analysis carried out in different laboratories and research centers has given different results, with limited overlap or reduced statistical significance [1,2]. These differences are matters of important scientific discussions and, besides the different or poorly reproducible experimental protocols and analysis pipelines [3–5], are imputed to two main reasons:

1. Datasets often include small numbers of subjects (some tens) with respect to the number of variables (tens of thousands of genomic probes in human) [6,7];
2. The most complex pathologies, such as cancer, are heterogeneous and multifactorial, as a result of the alteration of multiple regulatory pathways and of the interplay between different genes and the environment, rather than referable to a single dysfunctional gene like in monogenic diseases [8,9]. A consequence of this is that data are characterized by many correlated features; different features may thus be selected under different settings.

Widely used methodologies for the identification of biomarkers using microarray data are based on computing differential gene expression by univariate statistical tests. Such approaches provide information on the effects of specific genes as individual features, whereas it is now widely recognized that the interplay between
weakly up/down regulated genes, although not significantly differentially expressed, might be extremely important to characterize a disease status [10–11]. Machine learning algorithms are, in principle, able to identify multivariate nonlinear combinations of features and have thus the possibility to select a more complete set of experimentally relevant gene features. In this context, classification methods are often used to select biomarker genes from microarray data. In a recent study [12], classification performance of different methods was compared across different microarray studies in terms of ability to select biomarkers discriminating between two conditions. Besides reaching good classification accuracy, obtaining stable list of biomarkers is critical both to understand the results from a biological point of view and to gain sufficient reliability on potential targets of clinical and pharmaceutical applications. The stability issue in feature selection has received much attention recently [13–16]. In a recent contribution, He and Yu [17] review existing stable feature selection methods for biomarker discovery.

As shown in [18], biomarker stability and accuracy are associated to task difficulty, and higher stability is found for higher accuracy. However, it is in principle possible to have a lack of stability due to the presence of many highly correlated features, even with accuracy equal to one. A first contribution of this work is the comparison of different classification methods in terms of consistency of lists of candidate biomarkers and classification accuracy. To this purpose, three real microarray datasets monitoring breast cancer patients with positive and negative estrogen receptor status are used; we compare biomarker lists from the three datasets as well as sets of sub-lists of different sample size obtained from each dataset.

A slightly different issue, although related with list stability, is the precision of biomarker identification, i.e. the ability to select true biomarkers, defined as features biologically related to the physiological or clinical condition under study as cause or effect of it. A second contribution of our work is the generation of a simulated dataset to assess alternative methods’ performance across multiple studies and varying number of samples, and to evaluate precision of feature selection on a benchmark with known biomarkers. We extensively simulate the effect of heterogeneity and variability on different sets of synthetic microarray data consisting of two balanced groups of 50, 20, 15 or 10 subjects. Sample heterogeneity characteristic of complex diseases is reproduced within the same group by simulating both intrinsic variability of the population and the alteration of regulatory mechanisms induced by the disease. Population variability is simulated by modeling evolution of a pool of subjects in terms of pairing, mutation and selection in order to generate individuals characterized by different genotypes. Then, a subset of this population undergoes alterations in regulatory mechanisms so to mimic the disease state; these perturbations are slightly different across the patients in the diseased group, so to reflect the lack of homogeneity among patients that is typically reported in the literature for complex diseases [8].

Different methods for binary classification and feature weighting and ranking are applied to both simulated and real data. In particular, the classical Support Vector Machine algorithm (SVM) [19] is used in its linear and Gaussian kernel versions, and the SVM weights are used for feature ranking. As an alternative, I-Relief [20] is also used as the feature ranking algorithm coupled with linear SVM. One method of totally different nature is also applied: the Spectral Regression version of the Discriminant Analysis algorithm (SRDA) both as a classifier and a feature weighting algorithm [21]. All methods make use of the Entropy-based version of the classical Recursive Feature Elimination procedure as ranking schema [22,23]. In all experiments, external cross-validation loops with separate training and test phases are employed to avoid overfitting effects such as selection bias [24]. Results are also compared with those obtained by using SAM, a widely applied variant of univariate statistical t-test [25].

Methods

Simulation of population variability

Each subject in the dataset was modeled by a regulatory network of $N=10000$ genes, based on the simulator described in [26], using default parameter settings. The topology is characterized by the connectivity matrix $W$, with weights $w_{ij}$ different from zero if gene-product $j$ directly affects the expression of gene $i$. The sign and the magnitude of $w_{ij}$ indicate the sign and the strength of the regulation. Differential equations were used to model the dynamics of transcription and degradation as continuous variables and to describe transcription delay with different time constants for each gene (see Text S1 for further details).

In molecular biology, transcription factors and enhancers are proteins that bind to specific DNA sequences and can regulate transcription of a gene by respectively activating/blocking the transcription and tuning the quantity of RNA transcribed in a unit of time. Loosely speaking, weights $w_{ij}$ of the connectivity matrix $W$ can be interpreted as the affinity of the genome specific sequences for a transcription factor or an enhancer $j$, regulating expression of a gene $i$. Since weights $w_{ij}$ can in principle be mapped to specific nucleotide sequences in the genome, $W$ can be interpreted as part of the genotype of the subject. Moreover, since each network is characterized by a finite number of attractors, reachable from a specific set of initial conditions and/or external stimuli, each attractor can be interpreted as the phenotype of an individual in a particular environmental condition.

Following these concepts, evolution of a population of $M=1000$ individuals was simulated using a procedure similar to the one described in [27]. In summary, subjects were modeled as regulatory networks of $N=10000$ nodes characterized by a specific genotype (the connectivity matrix $W$ with weights $w_{ij}$) and a specific phenotype (the system attractors). Given specific initial conditions (i.e. environment condition that we consider fixed for the purpose of this work), the initial population at generation 1 consisted of $M$ individuals with identical connectivity matrix $W$ and with $N$ dimensional vectors of expression values obtained by considering the steady state reached by the system. Gene specific kinetic parameters $\alpha$ and $\beta$ were sampled from Gaussian distributions with means $\mu_{\alpha, \beta}$ and standard deviations $\sigma_{\alpha, \sigma_{\beta}}$. For each subject, $\mu_{\alpha}$ and $\mu_{\beta}$ were set to 20 and 0.2, respectively, whereas $\sigma_{\alpha}$ and $\sigma_{\beta}$ were sampled from a Gaussian distribution with means 0.5 and 0.02 and standard deviations equal to 0.075 and 0.0025, respectively. Parameters values (Text S1, Equations 1 and 2) were empirically chosen so to generate in silico data with statistical distribution similar to those observed on the real datasets.

To introduce genotype variability in the population, subsequent generations were produced by iteration of three steps: random pairing of individuals, mutation of a randomly chosen subset of subjects and selection of the surviving subjects. For computational reasons, these three steps were applied only to a sub-network of size $N=900$, indicated as $W_{900}$ in the following, which was constrained to be not connected to any of the other 9100 nodes in the network. Each step is described in detail in what follows.

a. Pairing. Offspring was created by randomly selecting two parents among the current population of $M$ individuals and
randomly combining rows of the connectivity matrix $W_{900}$ from each parent with equal probability.

b. Mutation. Mutation was simulated by changing each nonzero $w_{ij}$ (which, by simulation, resulted equal to 1619 elements on a matrix of $900 \times 900 = 810000$ elements) with probability 0.025/1619. The new value of each mutated $w_{ij}$ was sampled from a Gaussian distribution with mean and standard deviation equal to 0 and 1, respectively. Therefore, at each iteration, each subject mutated with probability 0.025.

c. Selection. Assuming, in a naive simplification of reality, that individuals behaved as haploid organisms and that the initial phenotype was essential for survival, subjects with at least one mutated $w_{ij}$ were allowed to survive only if their phenotype did not change with respect to the original population. In practice, we calculated the Euclidean distance between the expression profile of each mutated subject (the $N$ dimensional vector of gene expression values at steady state) and the average expression profile of subjects at generation 1; if Euclidean distance exceeded the value of 0.81 (corresponding to the percentile 99.5 of the observed distances) the subject was eliminated, otherwise he/she survived. At each generation, $M$ individuals were generated, independently of the number of parents survived in the previous generation. Evolution proceeded for a time sufficient to have a final population of $M$ subjects with the same phenotype but different genotype, i.e. 150 generations (Figure S1).

Noise was added to expression data of the 10000 genes in the 1000 subjects as additive Gaussian noise with mean 0 and standard deviation sampled from the distribution of within-groups error variance in real datasets (paragraph 2.5), as described in [29]. In particular, the error variance associated to genes was approximated by a lognormal distribution with mean 0.22 and standard deviation 0.33.

Simulated data

Once the base population was simulated, two groups, each of 500 subjects, were defined. The pathological condition was simulated by knocking out or down six target hubs, defined as those genes with the highest out-degree and expression value at steady state higher than 0.88, so that their knock-out (down) achieved an effect. The knock-out of gene $j$ was simulated by setting to 0 its expression and all the elements of row $j$ in matrix $W$. Consistently, the knock-down of gene $j$ was simulated by halving its value and all the elements of row $j$ in matrix $W$. Diseased subjects had 4, 5 or 6 genes belonging to $W_{900}$ that were knocked out or down. The proportion of subjects with 4, 5 or 6 genes affected was set equal to 1/3, 1/3, 1/3, respectively. For each gene, the proportion of subjects affected by knock-out and knock-down was set equal to 1/3 and 2/3, respectively. Figure 1 displays the diseased group variability in terms of histogram of the Euclidean distance between the steady states of the original and the diseased population. The variability rises from both the intrinsic population variability, i.e. the different connectivity weights $w_{ij}$ in $W_{900}$, and the heterogeneity of the disease. Comparison between simulated and Affymetrix data (GSE2990, see below) showed that the datasets have very similar distribution (Wilcoxon test p-value equal to 0.9).

The putative biomarkers were defined as those genes directly or indirectly regulated by at least one of the six hubs, having expression modified by the knock-out (down). This resulted in 155 biomarkers on a total of 10000 features.

To consider the effect of sample size, we partitioned the two groups of 300 healthy and 500 diseased subjects into 4 sets of 10 balanced non-overlapping datasets of size 50, 20, 15 or 10 subjects per group (10 datasets for each case study), for a total of 40 simulated datasets.

Real data

Publicly available data from three breast cancer microarray studies were collected from Gene Expression Omnibus repository (GEO) with accession numbers: GSE2990 [29], GSE3494 [30] and GSE7390 [31].

Datasets were all hybridized using Affymetrix U133 Gene-chips™ (HG-U133A). Samples that have known estrogen-receptor (ER) status were selected so to have balanced groups (ER+ and ER−), homogeneous with respect to characteristics such as age, tumor size and histological grade. We chose to investigate the ER status because it is always assessed in breast biopsies, therefore it is very often present among the clinical/pathological information given with the datasets. Moreover, the assessment of the ER status is important to divide breast cancer into molecular classes and to treat cancer with the hormone blocking therapy [32]. Since there are subgroups of samples belonging to multiple datasets, redundant subjects were removed. The resulting datasets are characterized by 22207 features (probe sets) and 66 subjects for GSE2990 (33 ER+, 33 ER−), 50 subjects for GSE3494 (25 ER+, 25 ER−) and 92 subjects for GSE7390 (46 ER+, 46 ER−). Comparison among the three datasets allowed assessing list stability in a real case study. To assess list stability within dataset, thus not accounting for experimental setup variability, and to compare the effect of sample size with simulated data, 20 subjects per ER status were repeatedly sampled from datasets GSE2990 and GSE7390 to set up smaller balanced datasets (10 datasets for each case study). Gene expression intensity signal was derived and normalized independently for each dataset using the robust multarray average (RMA) algorithm [33]. Probe sets related to the estrogen receptor (ESR1) were removed from all datasets, since ESR1 is the gene more directly associated with ER status and can mask other potential descriptors of the underlying pathophysiology [34].

Biomarker discovery methods

Support Vector Machine (SVM). Support Vector Machines [19] are a set of supervised learning methods used for classification, in principle able to identify nonlinear features thus providing a more complete set of relevant genes. They were used here with linear (LSVM) and Gaussian kernel (GSVM). The tuning phase required the identification of the optimal value of the regularization parameter $\epsilon$ (the trade-off between empirical error and smoothness of the solution) and, for the Gaussian kernel, of the bandwidth $\sigma$.

Iterative-Relief and SVM (IR SVM). Iterative Relief [20] is a feature selection/ranking algorithm that solves a convex optimization problem with a margin-based objective function in

Figure 1. Variability of the diseased population. Histogram of the Euclidean distance between the steady states of the diseased population with respect to the original phenotype.
doi:10.1371/journal.pone.0032200.g001
a nearest-neighbor based strategy. The ranking provided by I-Relief can be used by an independent classifier: in our case, we used it together with linear SVM. The only required parameter to set is the bandwidth $\sigma$ of the internal kernel.

**Spectral Regression Discriminant Analysis (SRDA).**
SRDA algorithm embeds the classical Discriminant Analysis into a regression framework through the use of spectral graph analysis [21]. This improves computational efficiency by solving only a set of regularized least squares problems without eigenvector computation involved. Moreover, the score attributed to each feature can be interpreted as a feature weight, allowing directly feature ranking. The regularization value $\alpha$ is the only parameter we had to tune.

**Parameter Tuning.** For GSVM, IRSVM and SRDA, parameter tuning was performed through a preliminary 3-fold cross-validation (without feature ranking) run for a set of possible parameter values.

**Bootstrap.** The four methods, LSVM, GSVM, IRSVM and SRDA, were used both in single cross-validation and in a Monte Carlo bootstrap resampling schema with $B = 100$ external training/test splits with 3-fold cross-validation as internal resampling (methods named as LSVM_B, GSVM_B, IRSVM_B and SRDA_B in the following). This strategy has been proved to be an effective countermeasure against unwanted selection bias effects [23,24].

**Ranking and selection.** In the four aforementioned methods, the Entropy-based Recursive Feature Elimination (ERFE) procedure was used as the ranking schema [22]. Starting from the classical RFE algorithm [35], ERFE adaptively discards a subset of the least informative features according to an entropy measure of the distribution of the weights generated by the feature weighting schema. This guarantees a relevant speed-up of the ranking procedure without performance degradation. The optimal number of features was chosen in correspondence to the precision of the ranking procedure without performance degradation. This strategy has been proved to be an effective countermeasure against unwanted selection bias effects [23,24].

**Statistical analysis of Microarrays (SAM).** The SAM test [25] is a widely used univariate statistical test for the identification of differentially expressed genes from microarray data. This variant of the t-test accounts for the non Gaussian distribution of data. SAM uses a resampling procedure to derive the null hypothesis distribution and the false discovery rate (FDR) to account for multiple testing [36]. In this study, a FDR $= 5\%$ was used to select features after a ranking based on their p-value.

**Algorithm evaluation.**
Algorithm performance was evaluated in terms of the ability to select true biomarkers, to provide stable lists of biomarkers and to accurately classify the samples.

The ability to select the true biomarkers was evaluated in terms of precision (number of true positives divided by the number of selected features) obtained by the different methods according to their choice of the optimal number of features. The area under the precision-recall curve was also considered to outline the ability of the different methods to rank the features, a task related with the ability to select the true biomarkers.

To evaluate the ability of the different methods to provide stable lists of biomarkers, the algebraic stability indicator derived by Canberra distance was used [15]. In particular, given two ordered lists $T1$ and $T2$ of $p$ ranked features, the Canberra distance between them is defined as:

$$Ca(T1,T2) = \sum_{i=1}^{p} \frac{\tau_{1}(i) - \tau_{2}(i)}{\tau_{1}(i) + \tau_{2}(i)}$$

where $\tau_{1}(i)$ and $\tau_{2}(i)$ indicate the rank, i.e. the position, of feature $i$ in the ordered lists $T1$ and $T2$, respectively. The stability indicator for a given set of lists was computed as the mean of the Canberra distances between pairs of lists in the set, normalized by its expected value on the whole permutation group on $p$ features; the obtained value ranges then between 0 (maximal stability) and 1.4 (maximal instability), with 1 as the case of randomly generated lists. A different extension based on quotients of permutation groups allowed comparing lists $T1$ and $T2$ of different length $l_1, l_2$.

$$Ca(T1,T2) = \frac{1}{(p-l_1)! (p-l_2)!} \sum_{\text{all lists}} \sum_{\text{all possible subsets}} Ca(T1,T2)$$

where $p$ is the total number of analyzed features and $T_j (j=1,2)$ belong to the set $\mathcal{S}$ of all the lists having the first $l_j$ features ordered as in $T_j$ and the remaining $(p-l_j)$ elements ordered in all the $(p-l_j)!$ possible combinations. This is called the complete version of the partial lists distance: neglecting its component depending only on the discarded features we ended up with a different measure (called core distance) better tailored to highlight variations on partial short lists [37]. Full statements and proofs of the mathematical properties of the Canberra distance can be found in [38].

The Matthews correlation coefficient, $MCC$ [39], was used as a measure of the quality of binary classifications. The MCC can be calculated directly from the confusion matrix using the formula:

$$MCC = \frac{TP \cdot TN - FP \cdot FN}{\sqrt{(TP + FP)(TP + FN)(TN + FP)(TN + FN)}}$$

In this equation, $TP$ is the number of true positive, $TN$ the number of true negative, $FP$ the number of false positive and $FN$ the number of false negative subjects.

Statistical significance of the comparison between each method and its bootstrap variant was assessed using Wilcoxon signed ranks test with significance level $\alpha$ equal to 0.05. Differences among the four multivariate feature selection methods in their bootstrap variant were assessed using Friedman test ($\alpha = 0.05$), followed, if significant, by Wilcoxon signed ranks test to examine between which methods the differences actually occur, with a significance level $\alpha$ equal to 0.05/6 = 0.0083 to correct for multiple testing. Finally, SAM was compared with the other eight methods using Wilcoxon signed ranks test with a significance level $\alpha$ equal to 0.05/8 = 0.00625 to correct for multiple testing.

**Results**

**Simulated data**
Application of the nine biomarker discovery methods on the forty simulated datasets provides information on precision of feature selection, stability of biomarker lists and classification accuracy.

**Feature selection.** Figure 2 shows boxplots of precision, obtained by the different methods according to their choice of the optimal number of features. Feature selection results show that bootstrap resampling schema leads to an improvement in terms of precision, statistically significant when the sample size decreases. In particular, with 20, 15 and 10 subjects per group, bootstrap improves precision of 1.5, 1.4 and 2 fold change, respectively (average improvement across the four different classification methods). Differences between bootstrap and non-bootstrap approach are statistically significant (p-value lower than 0.05, Wilcoxon signed ranks test) for LSVM and GSVM with 20
subjects per group, for LSVM and SRDA with 15 subjects per group, for all methods but LSVM with 10 subjects per group. In Figure 2, the interquartile range of the number of selected features is also reported. Interestingly, with less than 50 subjects per group, the bootstrap approaches have the tendency to select a lower number of features.

There are no appreciable differences among different bootstrap methods in terms of precision (Friedman test p-value always above 0.05 for every sample size). In the case of 50 subjects per group, SAM detects differentially expressed features with average precision comparable to that obtained by the other methods, but GSVM, IRSVM and IRSVM_B, which perform statistically significantly better than SAM (p-value equal to 0.002, 0.006, 0.006 respectively, Wilcoxon signed ranks test). With 20 subjects per group, SAM is not able to select any gene with FDR lower than 0.05 in six datasets, whereas in the remaining four, it selects in average 50 features with high precision (0.85 in average). In these latter cases, SAM performs statistically significantly better than LSVM, with 10 subjects per group. In Figure 2, the interquartile range of the number of selected features is also reported below each boxplot.

doi:10.1371/journal.pone.0032200.g002

Figure 2. Precision of feature selection on simulated data.
Boxplots of precision corresponding to the optimal number of features chosen by different methods when 50, 20, 15 or 10 subjects per group are available. A star highlights the significant differences between pair of bootstrap and non-bootstrap approaches (p-value lower than 0.05, Wilcoxon test). The interquartile range of the number of selected features is also reported below each boxplot.

doi:10.1371/journal.pone.0032200.g002

With 50 and 20 subjects per group, a simple univariate test such as SAM is able to rank differentially expressed features with performance comparable to multivariate methods such as LSVM, GSVM, SRDA and their bootstrap versions, but not to IRSVM and IRSVM_B that perform better (p-value equal to 0.002 for both tests). However, when the number of subjects is lower than 20, SAM performance in feature ranking dramatically drops with respect to classification based methods (p-value lower than 0.002 for all comparisons but GSVM and GSVM_B). This behavior is consistent with the inability of SAM to select any feature with 15 and 10 subjects per group.

**Feature stability.** The ability of the various methods to select the same features across different datasets is depicted in Figure 4, where the boxplots of the core Canberra distance (Equation 2) of the lists of selected features are shown. The distance between the ranked lists increases for all the methods when the number of subjects per group decreases. Results are consistent with those obtained for feature selection: the bootstrap resampling schema leads to an improvement in list stability, statistically significant when sample size decreases. In particular, differences are statistically significant for LSVM, SRDA and IRSVM with 20 subjects per group (p-value always lower than 0.036), for LSVM, GSVM and IRSVM with 15 subjects per group (p-value always lower than 0.033), for all methods with 10 subjects per group (p-value always lower than 0.001). Among bootstrap approaches, IRSVM_B is the best performing method in terms of list stability, when 20 subjects per group are available; LSVM_B performs as IRSVM_B in the case of 15 subjects per group; GSVM_B performs as IRSVM_B in the case of 10 subjects per group (Friedman test gave p-value lower than 10^-11 for sample

---

**Figure 3. Evaluation of feature ranking on simulated data.**
Boxplots of area under the precision vs. recall curves obtained by ranking features according to the different methods, when 50, 20, 15 or 10 subjects per group are available.

doi:10.1371/journal.pone.0032200.g003
size 20, 15, 10 and Wilcoxon signed ranks test gave p-value lower than 0.001 for every significant pairwise comparison.

In the case of 50 subjects per group, SAM shows list stability comparable to the one obtained by the other methods. With 20 subjects per group, SAM is as good as IRSVM_B; however, results are limited to the four datasets for which SAM was able to select features below the 0.05 FDR threshold. As for feature selection, with less than 20 subjects per group we do not report any results since SAM was not able to select any gene in any of the dataset.

**Classification Accuracy.** Bootstrap approach also improves classification accuracy (Table 1): with 50 subjects per group LSVM_B and IRSVM_B perform better than their standard versions (p-value equal to 0.019 and 0.007, respectively); with 20 subjects per group GSVM_B and SRDA_B perform better than their standard versions (p-value equal to 0.030 and 0.025, respectively); with 15 subjects per group L SVM_B, GSVM_B and SRDA_B perform better than their standard versions (p-value equal to 0.031, 0.031 and 0.016, respectively). All bootstrap classification methods perform equally well (Friedman test p-values always above 0.15 for every sample size) in terms of classification accuracy. SAM was excluded from this part of the analysis.

**Real Data**

Application of the various methods on breast cancer data provides information on list stability and classification accuracy.

Results on dataset GSE3494 are not shown since none of the different methods gave good accuracy (MCC always below 0.4). On the other two datasets, results confirmed those obtained by simulated data. In particular, bootstrap resampling schema leads to an improvement in list stability (Figure 5), appreciable both when the complete datasets GSE2990 and GSE7390 are compared and when 20 subjects per group are repeatedly sampled from each dataset, for a total of 10 resampled dataset for each of the original datasets.

Differences between bootstrap and standard approach are statistically significant for every method (p-value always lower than 0.002) with dataset GSE2990 and for LSVM and GSVM with dataset GSE7390.

In terms of stability, SAM performance is poor: when 20 subjects per group are repeatedly sampled from each dataset the core Canberra distance between lists of biomarkers ranges between 0.04 and 0.37 (average 0.27) for GSE2990 and between 0.13 and 0.31 (average 0.22) for GSE7390; on the other hand, between the complete datasets (GSE2990 vs. GSE7390) the core Canberra distance is equal to 0.63. SAM results are not shown in Figure 5 to avoid masking the differences among the other methods.

The MCC obtained using different methods on real datasets is shown in Table 2. The first two columns report the MCC for GSE2990 and GSE7390, respectively, when 20 subjects per group are repeatedly sampled from each dataset. The third and fourth columns of Table 2 report the MCC obtained using the complete datasets GSE2990 and GSE7390. Results are comparable to those obtained using simulated data. Bootstrap approach improves classification accuracy on dataset 7390 for all methods (p-value equal to 0.02, 0.04, 0.001, 0.03 for LSVM_B, GSVM_B, SRDA_B and IRSVM_B, respectively, with respect to their standard version), whereas, with dataset 2990, the differences between bootstrap and standard approaches are not statistically significant. It is confirmed the tendency of the bootstrap approaches to select a lower number of features. As observed with simulated data, all bootstrap classification methods perform equally well in terms of classification accuracy (Friedman test p-values always above 0.06 on both the datasets).

To improve our confidence in the biological meaningfulness of the results obtained with real data, the functional annotation of the selected genes was considered. In particular, we considered: 1) the intersection of the lists obtained by the four bootstrap methods on datasets GSE2990 and GSE7390; 2) the intersection of the lists obtained by IRSVM_B on datasets GSE2990 and GSE7390. The two lists of genes and the results of enrichment analysis are available in Text S2.

**Discussion**

The identification of an appropriate and robust biomarker signature of a disease is a fundamental step for early diagnosis and
both intrinsic variability of the population and heterogeneity of the disease. Despite its simplicity with respect to real systems, the simulator provides a versatile test bed to assess a wide spectrum of methodologies. The dataset is available upon request (barbara.dicamillo@dei.unipd.it).

Results on simulated data show that when some tens of subjects are available per group, performance of different methods are comparable. However, when available subjects are equal or lower than 20, bootstrap resampling schema leads to an improvement in the precision of the selected features and list stability. Bootstrap approach slightly improves also classification accuracy when 50, 20 or 15 subjects per group are available. Among the different methods here considered, IRSVM_B provides the best combination of feature ranking and biomarker stability; moreover, it reaches the best average performance also in terms of classification accuracy.

In the case of 50 subjects per group, a simple univariate test such as SAM shows performance comparable to that obtained by the other methods. With 20 subjects per group, SAM performance strongly depends on the dataset: on the simulated data, for example, SAM is not able to select any gene with FDR lower than 0.05 in six datasets, whereas in the remaining four, it selects in average 50 features with high precision (0.85 in average) and stability comparable to the one obtained using IRSVM_B, although this latter outperforms SAM in feature ranking. Finally, with less than 20 subjects per group, SAM performance dramatically drops with respect to classification based methods.

With real data, only list stability and classification accuracy can be assessed. In both cases, results of classification methods tightly resemble those obtained with simulated data.

In conclusion, our analysis confirms the MAQC-II indication that comparably good classification accuracy can be reached by different methods on the same task, provided that a valid Data Analysis Plan is adopted [18]. Furthermore, we found a systematic improvement due to bootstrap in selecting features with a high degree of precision and stability. Overall, the crucial factor affecting list stability seems to be that the classification task is under constrained. When additional information is present on the relationships between genes, this information could be used to improve the stability with respect to the features of the classifiers.

The basic idea of this strategy would be to take into account the complex gene relationships, instead of considering genes as independent features. In future works, we plan to compare the

**Table 2. MCC corresponding to the optimal number of features obtained using different methods – real data.**

|                  | GSE2990 20 subjects | GSE7390 20 subjects | GSE2990 | GSE7390 |
|------------------|---------------------|---------------------|---------|---------|
| LSVM             | 0.64 (0.61, 0.69)   | 0.77 (0.61, 0.90)   | 0.60    | 0.79    |
| LSVM_B           | 0.65 (0.51, 0.77)   | 0.81 (0.58, 0.91)   | 0.68    | 0.81    |
| GSVM             | 0.62 (0.59, 0.64)   | 0.73 (0.60, 0.83)   | 0.59    | 0.74    |
| GSVM_B           | 0.65 (0.60, 0.71)   | 0.78 (0.61, 0.91)   | 0.61    | 0.77    |
| SRDA             | 0.63 (0.61, 0.66)   | 0.74 (0.62, 0.85)   | 0.50    | 0.78    |
| SRDA_B           | 0.67 (0.61, 0.78)   | 0.83 (0.66, 0.90)   | 0.67    | 0.77    |
| IRSVM            | 0.62 (0.47, 0.69)   | 0.80 (0.65, 0.91)   | 0.60    | 0.78    |
| IRSVM_B          | 0.67 (0.58, 0.82)   | 0.82 (0.62, 0.91)   | 0.67    | 0.78    |

Average MCC obtained when 20 subjects per group are available, sampled from datasets GSE2990 and GSE7390 MCC (range of values is indicated in parenthesis), and obtained on the complete datasets GSE2990 and GSE7390. doi:10.1371/journal.pone.0032200.g002
use of different biological information from genomic databases in the learning process by integrating different prior knowledge like functional annotations, protein-protein interactions, and expression correlation among genes.

Supporting Information

Figure S1 Progression of population mutation with generations. Total number of subjects mutated with respect to survived subjects are represented for each generation.

Text S1 In Silico model of regulatory networks. (DOC)

Text S2 Selected genes. (DOC)

Acknowledgments

We would like to thank Dr. Marco Falda and Roberto Visintainer for their help in running the simulations.

Author Contributions

Conceived and designed the experiments: BDC. Analyzed the data: BDC TS MM GJ MS. Contributed reagents/materials/analysis tools: GJ AB CF. Wrote the paper: BDC TS FS. Supervised the study: GF GT CC.

References

1. Ein-Dor L, Kela I, Getz G, Givod D, Domany E (2005) Outcome signature genes in breast cancer: Is there a unique set? Bioinformatics 21(2): 171–178.
2. Boulesteix AL, Slawski M (2009) Stability and aggregation of ranked gene lists. Brief Bioinform 10(3): 556–568.
3. Larkin JE, Frank BC, Gavras H, Sultana R, Quackenbush J (2005) Indepepdence and reproducibility across microarray platforms. Nat Methods 2(5): 337–344.
4. Irizarry RA, Warren D, Spencer F, Kim IF, Biowal S, et al. (2005) Multiple-laboratory comparison of microarray platforms. Nat Methods 2(5): 345–350.
5. Ioannidis JP, Allison DB, Ball CA, Coohaly I, Cui X, et al. (2009) Repeatability of published microarray gene expression analyses. Nat Genet 41(2): 149–155.
6. Ein-Dor L, Tuk O, Domany E (2006) Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci U S A 103(15): 5923–5928.
7. Kim SY (2009) Effects of sample size on robustness and prediction accuracy of a prognostic gene signature. BMC Bioinformatics 10: 147.
8. Solé X, Bonifaci N, López-Bigas N, Berenguer A, Hernandez P, et al. (2009) Biological convergence of cancer signatures. PLoS One 4(2): e5494.
9. Chuang HY, Lee E, Liu YT, Lee D, Ideker T (2007) Network-based classification of breast cancer metastasis. Mol Syst Biol 3: 140.
10. Moortha VK, Lindgren CM, Eriksson KS, Subramanian A, Sihag S, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34(3): 267–273.
11. Subramanian A, Tamayo P, Mothoa VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression proﬁles. Proc Natl Acad Sci U S A 102(43): 15545–15550.
12. Bunea A, Rischmahl M, Kuner R, Tresch A (2009) Classification across gene expression microarray studies. BMC Bioinformatics 10: 453.
13. Davis CA, Gerck F, Hintermair V, Friedel CC, Fundel K, et al. (2006) Reliable gene signatures for microarray classification: Assessment of stability and performance. Bioinformatics 22(19): 2366–2363.
14. Zucknick M, Richardson S, Barla A, Paoli S, Galea A, et al. (2008) Algebraic stability indicators for ranked lists in molecular profiling. Bioinformatics 24(2): 256–264.
15. Abeel T, Helleputte T, Van de Peer Y, Dupont P, Saey Y (2010) Robust biomarker identification for cancer diagnosis with ensemble feature selection methods. Bioinformatics 26(3): 392–398.
16. He Z, Yu W (2010) Stable feature selection for biomarker discovery. Comput Biol Chem 34: 213–223.
17. Shi L, Campbell G, Jones WD, Campagne F, Wen Z, et al. (2010) The MicroArray quality control (MAQC-II) study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 28(9): 927–938.
18. Vapnik VN (1998) Statistical Learning Theory. John Wiley and Sons New York. 736 p.
19. Sun Y (2007) Iterative RELIEF for feature weighting: Algorithms, theories, and applications. IEEE Trans Pattern Anal Mach Intell 29(6): 1035–1051.
20. Cai D, He X, Han J (2008) SRDA: An Efﬁcient Algorithm for Large-Scale Discriminant Analysis. IEEE Trans Knowledge and Data Eng 20: 1–12.
21. Furlanello C, Seraﬁni M, Merler S, Jurman G (2003) Entropy-based gene ranking without selection bias for the predictive classiﬁcation of microarray data. BMC Bioinformatics 4: 54.
22. Furlanello C, Seraﬁni M, Merler S, Jurman G (2005) Semisupervised learning for molecular proﬁling. IEEE/ACM Trans Comput Biol Bioinform 2: 110–118.
23. Ambroise C, McLachlan GJ (2002) Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci U S A 99(10): 6562–6566.
24. Tusher VG, Tibshirani R, Chu G (2001) Signiﬁcance analysis of microarrays applied to the ‘ionizing radiation response. Proc Natl Acad Sci U S A 98(9): 5116–5121.
25. Di Camillo B, Toffolo G, Cobelli C (2009) A gene network simulator to assess reverse engineering algorithms. Ann N Y Acad Sci 1138: 125–142.
26. Segal ML, Bergman A (2002) Waddington’s canalization revisited: Developmental stability and evolution. Proc Natl Acad Sci U S A 99(16): 10528–10532.
27. Jurman G, Merler S, Stronach EA (2008) Comparing the characteristics of gene expression proﬁles derived by univariate and multivariate classiﬁcation methods. Stat Appl Genet Mol Biol 7: Article7.
28. Davis CA, Gerck F, Hintermair V, Friedel CC, Fundel K, et al. (2006) Reliable gene signatures for microarray classiﬁcation: Assessment of stability and performance. Bioinformatics 22(19): 2366–2363.
29. Zucknick M, Richardson S, Barla A, Paoli S, Galea A, et al. (2008) Algebraic stability indicators for ranked lists in molecular proﬁling. Bioinformatics 24(2): 256–264.
30. Abeel T, Helleputte T, Van de Peer Y, Dupont P, Saey Y (2010) Robust biomarker identification for cancer diagnosis with ensemble feature selection methods. Bioinformatics 26(3): 392–398.
31. He Z, Yu W (2010) Stable feature selection for biomarker discovery. Comput Biol Chem 34: 213–223.
32. Shi L, Campbell G, Jones WD, Campagne F, Wen Z, et al. (2010) The MicroArray quality control (MAQC-II) study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol 28(9): 927–938.
33. Vapnik VN (1998) Statistical Learning Theory. John Wiley and Sons New York. 736 p.
34. Sun Y (2007) Iterative RELIEF for feature weighting: Algorithms, theories, and applications. IEEE Trans Pattern Anal Mach Intell 29(6): 1035–1051.
35. Cai D, He X, Han J (2008) SRDA: An Efﬁcient Algorithm for Large-Scale Discriminant Analysis. IEEE Trans Knowledge and Data Eng 20: 1–12.
36. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: a Practical and Powerful Approach to multiple testing. J R Statist Soc B 57: 289–300.
37. Jurman G, Riccadonna S, Visintainer R, Furlanello C (2010) Algebraic Comparison of Partial Lists in Bioinformatics. arXiv:1004.1341v1.
38. Di Camillo B, Toffolo G, Cobelli C (2009) A gene network simulator to assess reverse engineering algorithms. Ann N Y Acad Sci 1138: 125–142.
39. Segal ML, Bergman A (2002) Waddington’s canalization revisited: Developmental stability and evolution. Proc Natl Acad Sci U S A 99(16): 10528–10532.
40. Jurman G, Riccadonna S, Visintainer R, Furlanello C (2010) Algebraic Comparison of Partial Lists in Bioinformatics. arXiv:1004.1341v1.
41. Jurman G, Riccadonna S, Visintainer R, Furlanello C (2009) Sample Heterogeneity Effect on Biomarker Discovery.